Surgical management of fibrotic encapsulation of the fluocinolone acetonide implant in CAPN5-associated proliferative vitreoretinopathy

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 1093-1098

  Tlucek, Paul S ^a   Folk, James C ^a   Sobol, Warren M ^b   Mahajan, Vinit B ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b Retina Physicians and Surgeons   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

ADNIV; Autosomal dominant neovascular inflammatory vitreoretinopathy; Calpain 5; CAPN5; Fibrotic encapsulation; Fluocinolone acetonide; Retisert

Indexed keywords

AZATHIOPRINE; FLUOCINOLONE ACETONIDE; PREDNISONE; TRIAMCINOLONE ACETONIDE;

ADULT; ANTERIOR EYE CHAMBER DEPTH; ARTICLE; AUTOSOMAL DOMINANT NEOVASCULAR INFLAMMATORY VITREORETINOPATHY; CAPN5 GENE; CASE REPORT; CATARACT EXTRACTION; DRUG CAPSULE; DRUG IMPLANT; EPIRETINAL MEMBRANE; EYE INFLAMMATION; FEMALE; FIBROSIS; FIBROTIC ENCAPSULATION OF DRUG IMPLANT; GENE MUTATION; GENOTYPE; HUMAN; LENS IMPLANTATION; MEDICAL DEVICE COMPLICATION; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETINA TEAR; SCLERA BUCKLING PROCEDURE; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY; VITREOUS HEMORRHAGE;

EID: 84878960804     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Mahajan VB, Skeie JM, Bassuk AG, et al. Calpain-5 mutations cause autoimmune uveitis, retinal neovascularization, and photoreceptor degeneration. PLoS Genet. 2012;8(10):e1003001.
2. Bennett SR, Folk JC, Kimura AE, Russell SR, Stone EM, Raphtis EM. Autosomal dominant neovascular inflammatory vitreoretinopathy. Ophthalmology. 1990;97(9):1125-1135.
3. Mahajan VB, Vallone JG, Lin JH, et al. T-cell infiltration in autosomal dominant neovascular inflammatory vitreoretinopathy. Molecular Vision. 2010;16:1034-1040.
4. Tlucek PS, Folk JC, Orien JA, Stone EM, Mahajan VB. Inhibition of neovascularization but not fibrosis with the fluocinolone acetonide implant in autosomal dominant neovascular inflammatory vitreoretinopathy. Arch Ophthalmol. 2012;130(11):1395-1401.
5. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005;112(7):1192-1198.
6. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arc Ophthalmol. 2008;126(9):1191-1201.
7. Bandello F, Polito A, Pognuz DR, Monaco P, Dimastrogiovanni A, Paissios J. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol. 2006;124(5):643-650.
8. Chan CK, Ip MS, Vanveldhuisen PC, et al; SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion. Ophthalmology. 2011;118(7):1364-1372.
9. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2001;131(4):468-471.
10. Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol. 2005;40(5):598-604.
11. Chen W, Chen H, Hou P, Fok A, Hu Y, Lam DS. Midterm results of low-dose intravitreal triamcinolone as adjunctive treatment for proliferative vitreoretinopathy. Retina. 2011;31(6):1137-1142.
12. Ahmadieh H, Feghhi M, Tabatabaei H, Shoeibi N, Ramezani A, Mohebbi MR. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology. 2008;115(11):1938-1943.
13. Tang L, Eaton JW. Inflammatory responses to biomaterials. Am J Clin Pathol. 1995;103(4):466-471.
14. Tang L, Eaton JW. Natural responses to unnatural materials: A molecular mechanism for foreign body reactions. Mol Med. 1999;5(6):351-358.
15. Mahajan VB, Gehrs KM, Goldstein DA, Fischer DH, Lopez JS, Folk JC. Management of sympathetic ophthalmia with the fluocinolone acetonide implant. Ophthalmology. 2009;116(3):552-557.
16. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011;118(8):1580-1587.
17. Patel CC, Mandava N, Oliver SC, Braverman R, Quiroz-Mercado H, Olson JL. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert). Retina. 2012;32(3):537-542.
18. Tarantola RM, Graff JM, Somani R, Mahajan VB. Temporal approach for small-gauge pars plana vitrectomy combined with anterior segment surgery. Retina. 2012;32(8):1614-1623.
19. Dehghan MH, Ahmadieh H, Soheilian M, et al. Effect of oral prednisolone on visual outcomes and complications after scleral buckling. Eur J Ophthalmol. 2010;20(2):419-423.
20. Galor A, Margolis R, Kaiser PK, Lowder CY. Vitreous band formation and the sustained-release, intravitreal fluocinolone (Retisert) implant. Arch Ophthalmol. 2007;125(6):836-838.
21. Jain N, Stinnett SS, Jaffe GJ. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. Ophthalmology. 2012; 119(1):132-137.
22. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118(10): 1916-1926.
23. Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010;117(3): 567-575.
24. Ahmad ZM, Hughes BA, Abrams GW, Mahmoud TH. Combined posterior chamber intraocular lens, vitrectomy, Retisert, and pars plana tube in noninfectious uveitis. Arch Ophthalmol. 2012;130(7):908-913.
25. Molteno AC, Fucik M, Dempster AG, Bevin TH; Otago Glaucoma Surgery Outcome Study: factors controlling capsule fibrosis around Molteno implants with histopathological correlation. Ophthalmology. 2003;110(11):2198-2206.
26. Polikov VS, Tresco PA, Reichert WM. Response of brain tissue to chronically implanted neural electrodes. J Neurosci Methods. 2005; 148(1):1-18.
27. Bohl A, Rohm HW, Ceschi P, et al. Development of a specially tailored local drug delivery system for the prevention of fibrosis after insertion of cochlear implants into the inner ear. J Mater Sci Mater Med. 2012; 23(9):2151-2162.
28. Parratte S, Boyer P, Piriou P, et al. Total knee replacement following intra-articular malunion. Orthop Traumatol Surg Res. 2011; 97(Suppl 6):S118-S123.
29. Butler KR Jr, Benghuzzi HA. Immunohistochemical detection of cytokine expression in tissue-implant response associated with TCP bioceramic implants loaded with steroid hormones. Biomed Sci Instrum. 2003;39:541-546.
30. Hickey T, Kreutzer D, Burgess DJ, Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J Biomed Mater Res. 2002;61(2):180-187.
31. Patil SD, Papadimitrakopoulos F, Burgess DJ. Dexamethasone-loaded poly(lactic-co-glycolic) acid microspheres/poly(vinyl alcohol) hydrogel composite coatings for inflammation control. Diabetes Technol Ther. 2004;6(6):887-897.